GCCA
10.5.2022 01:03:12 CEST | Business Wire | Press release
The Global Cement and Concrete Association (GCCA) has today revealed the first six start-ups that will be backed by its member companies as part of the first ever Innovandi ‘Open Challenge’ in the race to ‘net zero’ by 2050.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005690/en/
The six start-ups, which were chosen from more than 100 entrants to the Open Challenge, hail from the USA, Canada, UK, Italy and the Netherlands. They have now joined forces with world-leading cement companies to help drive further innovation in the industry and will each form part of formal consortia to further test, develop and deploy their ground-breaking technologies.
One of the key focuses of the industry is to develop the technology and implementation for carbon capture, utilisation and storage (CCUS), with CarbonOrO, MOF Technologies and Saipem among the start-ups that the industry is backing. GCCA members have committed to moving from the dozens of pilot projects and announcement already underway to having 10 industrial scale carbon capture plants by 2030 as part of the landmark Net Zero Roadmap, announced in October 2021. CCUS includes a range of technologies and methods that “capture” CO2 from large sources – such as in industrial power generation. The CO2 is then either used on site or compressed and transported to be used or stored elsewhere.
Carbon Upcycling Technologies and Fortera both use captured CO2 to produce low-carbon cement and cementitious materials. The other confirmed start-up is Coomtech, a British business that has developed a low-cost drying technology using kinetic energy created by managed, turbulent air.
Six newly established consortia will help to accelerate the development of technologies that reduce or eliminate carbon throughout the cement and concrete value chain. Each consortium is made up of a start-up company, with their respective pioneering technology, and includes between three and eight cement companies, with 16 GCCA member companies involved across the six innovation consortia.
Thomas Guillot, GCCA Chief Executive , said: “It’s a proud moment to see the industry coming together to support such innovative start-ups on their journey. Our member companies were greatly impressed by their ambition to be a key part of the climate solution. The programme is another big step forward towards unlocking innovation to help us achieve our net zero goal.
“As the need for resilient and sustainable communities to support a growing global population becomes more pressing, cement and concrete will be essential to providing the infrastructure and buildings that society needs. Achieving net zero concrete relies on a number of different groups playing their part, and as an industry we’re looking outwards as well as inwards, to see how start-ups like these can support our goals.
"To achieve net zero globally by 2050, we also need to involve and support the future generations who contribute innovative ideas and energy to the industry. At GCCA, we’re identifying and convening research and development with great potential and offering our support through guidance and effective collaboration.”
These young start-ups are the future generation to help accelerate the industry’s progress, and as an accelerator of the United Nations (UN) Race to Zero campaign, GCCA continues to support innovative development to achieve net zero concrete globally.
The members of each consortia are working together to develop their technologies ahead of a demonstration day, scheduled for late 2022. GCCA worked with Techstars, the worldwide network that helps entrepreneurs succeed, to identify start-ups for the challenge. To find out more about the Innovandi programme please visit https://gccassociation.org/innovandi/ .
ENDS
About the Innovandi Open Challenge
Launched in 2021 the Open Challenge is a key part of the industry’s commitment to achieve net zero. This first-ever edition provides the platform for start-ups to drive innovation in the cement and concrete sectors. The Open Challenge focuses on developing carbon capture and calcination technologies, as well as improving carbon use in the construction supply chain and the recycling process of concrete. By partnering with the start-ups, member companies will provide them with their global resources and the support they need to grow and refine their product.
Shortlisted start-ups that have not yet formed formal consortia are being mentored by GCCA to help develop their technologies. Further consortia are expected to be announced in the course of the next weeks.
In addition to the formal consortia, the Open Challenge has led to two GCCA members (Cementos Argos and Holcim) supporting Minus Materials as industrial partners in the US Department of Energy ARPA-E grant for $3 million.
The six shortlisted start-ups are:
-
CarbonOrO
(The Netherlands)
- Carbon capture technology using unique bi-phasic amine with a lower cost of capture.
- Supported by CEMEX, Holcim, SCG, Titan Cement, UltraTech Cement and Votorantim Cimentos.
-
Carbon Upcycling Technologies
(Canada)
- Using a patented, low-energy process, Carbon Upcycling Technologies chemically activates and captures CO2 within solid waste materials to produce a range of supplementary cementitious materials, to create low carbon cement and concrete.
- Supported by Cementos Argos, CEMEX, CRH, Holcim, Shree Cement and Taiheiyo.
-
Coomtech
(UK)
- Coomtech has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture.
- revolutionising a 100-year-old process, a single Coomtech-enabled plant can cut CO2 emissions by the equivalent of more than 600,000 mature trees per year and is 75% cheaper to operate.
- Supported by Buzzi Unicem, CRH, JSW Cement and UltraTech Cement.
-
Fortera
(USA)
- Fortera’s technology captures CO2 emissions from cement plants, combining it with calcium to make reactive calcium carbonate. It is stable in dry powder form and its cementitious properties are activated when wetted.
- Supported by Cementos Argos, CRH, Holcim, JSW Cement, Taiheiyo Cement and Ultratech Cement.
-
MOF
Technologies
(UK)
- Nuada carbon capture technology uses Metal-Organic Frameworks (MOFs) to deliver energy-efficient CO2 removal at a fraction of the cost of conventional amines
- Supported by Buzzi Unicem, Cementir Holding and HeidelbergCement,
-
SAIPEM
(Italy)
- Saipem has developed a revolutionary carbon capture technology using a non-volatile aqueous carbonate solution catalysed by enzymes that neither require nor produce toxic products. The process can capture post-combustion emissions directly from industrial sources, like chimneys, using low-grade residual heat to drive the process.
- Supported by Buzzi Unicem, Cementir Holding, Cementos Molins, CEMEX, GCC, Holcim, Titan Cement and Votorantim Cimentos.
Supporting quotes
Start-ups
Jan Hoppenbrouwers, Co-Owner and Head of Sales & Marketing, CarbonOrO
“There is a lot of talk about CCUS, but worldwide, there is only a limited number of active test projects lined up so far. With so little time left, this makes you wonder. GCCA members and their consortia’s joined efforts have all the characteristics to change this. Thank you for that.”
Natalie Giglio, Senior Business Development Associate, Carbon Upcycling Technologies
“At Carbon Upcycling, we've created a novel technology that uses CO2
as a resource rather than a waste for the cement industry. By using abundant, local waste materials and CO2
directly from cement kilns, we enable circularity within local supply chains. Participating in the Innovandi Open Challenge has given us a platform to take our ready-to-deploy technology and accelerate its pathway to global commercialisation."
Chris Every, Chief Commercial Officer & Founder, Coomtech
“As a young business seeking to establish a radical new technology there is usually no short cut to the industries you are targeting or clients you seek to inform and demonstrate capability to. Each prospect must be individually developed and nurtured. The Innovandi Open Challenge combines a stringent review process with access to the combined power of the biggest global players in the cementitious market. The Challenge provides those of us who have succeeded in clearing the evaluation hurdles along the way, a unique and hugely valuable direct access to our prospective markets and technology users. We are delighted and proud to have been selected as a consortium partner in the Innovandi Open Challenge and are excited to begin the execution stage, delivering Coomtech’s contribution to a cleaner and more cost-effective cement industry.”
Ryan Gilliam, CEO, Fortera
“We’re very pleased that our technology has been chosen by the Innovandi Open Challenge for industry collaboration. Fortera has developed a process for manufacturing cost-competitive, low-carbon cement at a time when net-zero solutions are urgently needed. We look forward to our collaboration with GCCA partners in furthering climate-friendly alternatives that deliver the cost and performance of Portland cement while sequestering carbon within the built environment.”
Dr. Conor Hamil, Co-CEO, MOF Technologies
“Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to be working with members of the GCCA to bring our technology to the field. Our Nuada carbon capture technology has been designed to deliver the ultra-efficient CO2
separation needed to overcome these barriers, enabling our partners to reach their net zero targets. We are therefore thrilled to be participating in the Innovandi Open Challenge and playing our part in decarbonising the concrete value chain.”
Saipem
“Saipem is proud to attract GCCA members’ interest in its unique enzymatic carbon capture technology. GCCA’s open innovation program positively contributes to accelerating the adoption of carbon capture technologies. SAIPEM will work with GCCA consortium members to improve from traditional carbon capture technologies’ environmental and energy footprint, helping the cement sector decarbonize its operations competitively while positively impacting many other hard-to-abate industrial sectors. This recognition further confirms Saipem’s leading role in the CCUS sector, where Saipem has the competencies, skills, assets and technologies to serve the entire value chain.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005690/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
